The FDA has been in discussions with OpenAI regarding the agency’s use of artificial intelligence, Wired reported May 8, citing sources familiar with the talks.
Here are four things to know:
- A small team from OpenAI has met multiple times in recent weeks with the FDA and two individuals associated with Elon Musk’s Department of Government Efficiency, according to the report.
- The group has discussed a potential project referred to as “cderGPT,” believed to be named after the FDA’s Center for Drug Evaluation and Research, which oversees prescription and over-the-counter medications in the U.S. Another initiative, “Research GPT,” was also discussed.
- Jeremy Walsh, the FDA’s recently appointed first artificial intelligence officer, has led the meetings. No contracts have been signed as of yet, sources told Wired.
- OpenAI declined to comment to Wired.
